Scelte terapeutiche e trattamento con sorafenib nell’epatocarcinoma: analisi finale dello studio GIDEON in Italia

Lydia Giannitrapani, Giammarco Fava, Rita Cengarle, Ilaria Proserpio, Michela E. Burlone, Vito Lorusso, Mario Angelico, Riccardo Lencioni, Stefano Cascinu, Adolfo Attili, Simona Marenco, Erica Villa, Antonio Gasbarrini, Vincenzo Palmieri, Massimo Marignani, Alfonso Noto, Filiana Cuttone, Claudia Erminero, Lydia Giannitrapani, Salvatore D'AngeloAdolfo Attili, Giulia Magini, Salvatore D'Angelo, Alfonso Noto, Nicola Calvani, Teresa Zolfino, Salvatore Tumulo, Carlo Saitta, Nicola Calvani, Petros Giovanis, Vincenzo Montesarchio, Angela Buonadonna, Massimo Marignani, Domenico Germano, Alfonso Noto, Domenico Sansonno, Lory Saveria Crocè, Domenico Amoroso, Umberto Cillo, Guido Poggi, Antonio Picardi, Francesco Di Costanzo, Elena Massa, Sandro Barni, Antonio Benedetti, Giulia Magini

Risultato della ricerca: Articlepeer review

11 Citazioni (Scopus)


Summary. Introduction. Sorafenib, an oral multikinaseinhibitor, is the only targeted agent approved for the treatmentof patients with hepatocellular carcinoma (HCC) afterdemonstration to increase overall survival compared to placeboin two randomized phase III study. GIDEON (Global Investigationof therapeutic DEcisions in HCC and Of its treatmentwith sorafeNib) is the largest, global, non-interventional,prospective study of patients with uHCC (n>3200)treated with sorafenib in real-life clinical practice conditions.Here we report the final analysis of safety and efficacy in theItalian cohort of patients. Methods. Patients with unresectableHCC who are candidates for systemic therapy, and forwhom a decision has been made to treat with sorafenib, areeligible for inclusion. Patients demographics disease characteristicsand treatment history were recorded at baseline visit.Sorafenib dose, concomitant medications, performancestatus, liver function, adverse events and efficacy (survivaland response rate) were collected throughout the study.Results. In the Italian cohort of the GIDEON study 278 patientswere included in 36 centers. The global rate of adverseevents was 81%. Drug-related events accounted for 67%,mostly of grade 1 and 2, and only 8% were classified as serious.The most common were diarrhea (24%), fatigue (23%),dermatological (14%), rash/exfoliation (10%), hypertension(9%), hemorrage/bleeding of gastrointestinal tract (6%).Overall survival was 14.4 months and time to progression6.2 months. Objective responses were observed in 14 patients(5%) with 3 complete responses (1%). Stable diseasesof at least 6 weeks were observed in 113 patients (41%) witha 30% of disease control rate. Discussion. The safety profileof sorafenib in terms of rate and type of adverse events issimilar to that emerged in the global international GIDEONstudy as well as in the pivotal registration studies.
Lingua originaleItalian
Numero di pagine10
RivistaRecenti Progressi in Medicina
Stato di pubblicazionePublished - 2015

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2700???

Cita questo